All In Biotech

Drug Trial Radar · NCT03083665

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization

Last checked: Nov 20, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 449 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

449

Actual

Start

Aug 22, 2017

Primary completion

Jun 30, 2022

Study completion Jun 30, 2022

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Mar 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (\>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects \>= 16 years to 80 years of age.

Conditions

  • Partial Seizures With or Without Secondary Generalization
  • Epilepsy

Interventions

  • PlaceboDrug

    * Pharmaceutical form: Film-coated tablets * Route of administration: Oral use

  • BrivaracetamDrug

    * Pharmaceutical form: Film-coated tablets * Concentration: 25 mg tablets and 50 mg tablets * Route of administration: Oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
  2. Percentage of Participants With Treatment-Emergent AEs (TEAEs) Leading to Study WithdrawalTime frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
  3. Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
  4. Partial Seizure Frequency Per 28 Days During the 12-week Treatment PeriodTime frame: From Baseline to 12-week Treatment Period

Locations

94 sites in 7 countries. Site status is shown where the registry gives one.

  • Ep0083 905

    Beijing, China

  • Ep0083 906

    Beijing, China

  • Ep0083 907

    Changchun, China

  • Ep0083 901

    Chengdu, China

  • Ep0083 902

    Guangzhou, China

  • Ep0083 909

    Guangzhou, China

  • Ep0083 917

    Guangzhou, China

  • Ep0083 920

    Guangzhou, China

  • Ep0083 922

    Guangzhou, China

  • Ep0083 924

    Guangzhou, China

  • Ep0083 912

    Hangzhou, China

  • Ep0083 908

    Lanzhou, China

  • Ep0083 921

    Nanchang, China

  • Ep0083 926

    Pingxiang, China

  • Ep0083 910

    Shijiazhuang, China

  • Ep0083 925

    Suzhou, China

  • Ep0083 913

    Wenzhou, China

  • Ep0083 927

    Xi'an, China

  • Ep0083 930

    Xinxiang, China

  • Ep0083 916

    Yinchuan, China

  • Ep0083 918

    Zhanjiang, China

  • Ep0083 904

    Zhengzhou, China

  • Ep0083 923

    Zunyi, China

  • Ep0083 148

    Adachi-ku, Japan

  • Ep0083 116

    Asaka, Japan

  • Ep0083 126

    Bunkyō City, Japan

  • Ep0083 127

    Bunkyō City, Japan

  • Ep0083 146

    Chiba, Japan

  • Ep0083 122

    Hachinohe, Japan

  • Ep0083 111

    Hamamatsu, Japan

  • Ep0083 141

    Higashisonogi-gun Kawatana-cho, Japan

  • Ep0083 110

    Hiroshima, Japan

  • Ep0083 121

    Itami, Japan

  • Ep0083 102

    Kagoshima, Japan

  • Ep0083 142

    Kamakura, Japan

  • Ep0083 140

    Kawasaki, Japan

  • Ep0083 123

    Kodaira, Japan

  • Ep0083 115

    Kokubunji, Japan

  • Ep0083 132

    Kōriyama, Japan

  • Ep0083 112

    Kōshi, Japan

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.